OTCMKTS:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis $1.00 0.00 (0.00%) As of 10/22/2026 03:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Eagle Pharmaceuticals Stock (OTCMKTS:EGRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eagle Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.95▼$1.0050-Day Range$0.16▼$3.9452-Week Range$0.00▼$3.94Volume200 shsAverage Volume7,454 shsMarket Capitalization$12.99 millionP/E Ratio0.85Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eagle Pharmaceuticals, Inc. was a specialty pharmaceutical company focused on developing and commercializing injectable and intranasal medicines, with an emphasis on products intended to improve existing therapies through differentiated formulations, dosing approaches, or delivery technologies. The company primarily served hospital, oncology, emergency medicine, and critical-care markets. Eagle’s marketed products included Ryanodex, an injectable formulation of dantrolene sodium used to treat malignant hyperthermia; Belrapzo, a formulation of bendamustine hydrochloride used in certain blood cancers; and Pemfexy, a ready-to-dilute formulation of pemetrexed used in the treatment of certain lung cancers and mesothelioma. Its commercial activities were concentrated mainly in the United States, with selected products and rights supported through external partners in international markets. Founded in 2007, Eagle was led for much of its history by founder and Chief Executive Officer Scott Tarriff. In 2024, Pharmacosmos A/S completed its acquisition of Eagle Pharmaceuticals, and Eagle became part of the Pharmacosmos Group. As a result, Eagle is no longer an independently traded company on the Nasdaq exchange, although its products and pharmaceutical operations continue under its parent organization. AI Generated. May Contain Errors. Read More Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EGRX Stock News HeadlinesEagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Above 50 Day Moving Average - Should You Sell?October 22 at 3:21 AM | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Above 50-Day Moving Average - What's Next?October 14, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 23 at 1:00 AM | Porter & Company (Ad)Eagle Pharmaceuticals Inc.August 27, 2026 | marketwatch.comDid Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 9, 2026 | prnewswire.comEagle Pharmaceuticals Announces Divestiture of BarhemsysJanuary 14, 2026 | globenewswire.comHALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSDecember 24, 2025 | prnewswire.comHalper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their RightsDecember 7, 2025 | businesswire.comSee More Headlines EGRX Stock Analysis - Frequently Asked Questions How have EGRX shares performed this year? Eagle Pharmaceuticals' stock was trading at $0.70 at the start of the year. Since then, EGRX stock has increased by 42.9% and is now trading at $1.00. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (OTCMKTS:EGRX) issued its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Bristol Myers Squibb (BMY), AbbVie (ABBV), Alibaba Group (BABA), Pfizer (PFE), AT&T (T) and Esperion Therapeutics (ESPR). Company Calendar Last Earnings11/09/2021Today10/23/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:EGRX Previous SymbolNASDAQ:EGRX CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees100Year Founded2007Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.85 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$257.55 million Price / Sales0.05 Cash Flow$2.50 per share Price / Cash Flow0.40 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares12,987,000Free Float9,234,000Market Cap$12.99 million OptionableNo Data Beta0.83 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:EGRX) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
